Bruce E. Sands
Icahn School of Medicine at Mount Sinai
H-index: 103
North America-United States
Top articles of Bruce E. Sands
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial | The Lancet Gastroenterology & Hepatology | Silvio Danese Remo Panaccione Brian G Feagan Anita Afzali David T Rubin | 2024/2/1 |
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD … | Gastroenterology | Silvio Danese Jean-Frederic Colombel Stephen Hanauer William Sandborn Bruce Sands | 2024/2/1 |
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease | Clinical Gastroenterology and Hepatology | Jean-Frédéric Colombel Bruce E Sands Christopher Gasink Benjamin Yeager Omoniyi J Adedokun | 2024/1/1 |
Two-year efficacy and safety of mirikizumab following 104 weeks of continuous treatment for ulcerative colitis: results from the LUCENT-3 open-label extension study | Inflammatory Bowel Diseases | Bruce E Sands Geert D’Haens David B Clemow Peter M Irving Jordan T Johns | 2024/3/9 |
Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme | Zeitschrift für Gastroenterologie | L Peyrin-Biroulet MC Dubinsky BE Sands J Panés S Schreiber | 2023/8 |
OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study | Journal of Crohn's and Colitis | M Ferrante S Danese M Chen G D'Haens S Ghosh | 2024/1/1 |
P568 Clinical relevance of baseline and change in Urgency Numeric Rating Scale score for mirikizumab treatment for Ulcerative Colitis | Journal of Crohn's and Colitis | D Clemow MC Dubinsky S Baygani BE Sands A Keohane | 2024/1/1 |
OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study | Journal of Crohn's and Colitis | V Jairath BE Sands P Bossuyt F Farraye M Ferrante | 2024/1/1 |
OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a … | Journal of Crohn's and Colitis | BE Sands R Panaccione G D'Haens S Schreiber A DuVall | 2024/1/1 |
P1013 Placebo rates in Crohn's disease: An individual patient data meta-analysis from multiple randomised controlled trials | Journal of Crohn's and Colitis | V Solitano M Hogan S Singh S Danese L Peyrin-Biroulet | 2024/1/1 |
Impact of Biologics and Small Molecule Agents on Postoperative Complications in Inflammatory Bowel Disease: A Systematic Review | Kate E Lee J Alexander Sizemore Grace Kim Bo Shen Bruce E Sands | 2024/1/31 | |
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS–POST HOC ANALYSIS OF LIBERTY-CD AND … | Inflammatory Bowel Diseases | Stefan Schreiber Jean-Frederic Colombel Stephen Hanauer William Sandborn Bruce Sands | 2024/2/1 |
Dietary Interventions and Supplementation in Patients With an Ileal Pouch–Anal Anastomosis: A Systematic Review | Stephanie Gold Carrie Levinson Jean-Frederic Colombel Laura Manning Bruce E Sands | 2024/3/7 | |
BOC. 04.2: TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY | Digestive and Liver Disease | BE Sands G D'haens DB Clemow PM Irving JT Johns | 2024/4/1 |
P637 Ozanimod efficacy with or without concomitant corticosteroids in 5-ASA–exposed, advanced therapy–naive, immunomodulator-naive patients with ulcerative colitis: a post hoc … | Journal of Crohn's and Colitis | S Horst M Fischer JA Kinnucan JS Sauk H Wu | 2024/1/1 |
DOP54 Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapy | Journal of Crohn's and Colitis | D Richards M Vetter M Germinaro B Verstockt R Atreya | 2024/1/1 |
P653 Impact of ozanimod on type III collagen turnover biomarkers and the association with ozanimod efficacy in patients with moderately to severely active ulcerative colitis … | Journal of Crohn's and Colitis | G D'Haens R Maddux C Wu Y Hu BE Sands | 2024/1/1 |
P862 Effects of induction and maintenance therapy with risankizumab on health-related quality of life outcomes in patients with moderately to severely active ulcerative colitis … | Journal of Crohn's and Colitis | J Panés EV Loftus Jr A Armuzzi B Siegmund BE Sands | 2024/1/1 |
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT Trials | Inflammatory Bowel Diseases | Geert D’Haens Peter DR Higgins Laurent Peyrin-Biroulet Bruce E Sands Scott Lee | 2024/1/25 |
P983 Treatment of patients with moderate-to-severe Crohn’s disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal … | Journal of Crohn's and Colitis | BE Sands MC Dubinsky G D’Haens S Schreiber S Danese | 2024/1/1 |
